Docetaxel Kabi 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0038 
C.I.2.a - Change in the SPC, Labelling or PL of a 
26/09/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IA/0037 
B.II.f.1.e - Stability of FP - Change to an approved 
02/06/2023 
n/a 
stability protocol 
IA/0036 
A.5.b - Administrative change - Change in the name 
21/03/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IA/0035 
B.III.1.a.2 - Submission of a new/updated or 
11/01/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0034 
B.II.b.3.z - Change in the manufacturing process of 
17/09/2021 
n/a 
the finished or intermediate product - Other variation 
IB/0033 
B.II.b.4.a - Change in the batch size (including batch 
26/02/2021 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IA/0032 
B.III.1.a.2 - Submission of a new/updated or 
14/01/2021 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0031/G 
This was an application for a group of variations. 
12/10/2020 
04/10/2021 
SmPC, Annex 
II and PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
C.I.2.a - Change in the SPC, Labelling or PL of a 
Page 2/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0030 
B.I.b.1.d - Change in the specification parameters 
28/08/2020 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IB/0029 
B.II.b.3.z - Change in the manufacturing process of 
03/04/2020 
n/a 
the finished or intermediate product - Other variation 
IB/0028 
Update of sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the 
31/01/2020 
24/02/2020 
SmPC and PL 
SmPC to include the treatment of patients with 
metastatic hormone-sensitive prostate cancer in 
combination with androgen-deprivation therapy 
(ADT), with or without prednisone or prednisolone. 
The Package Leaflet is updated accordingly.  
The changes have been implemented in line with the 
reference medicinal product.  
Additionally, MAH took the opportunity to correct 
minor editorial changes in SL, SK and RO Product 
Information. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 3/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
IAIN/0027 
B.II.b.1.a - Replacement or addition of a 
11/12/2019 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
II/0022 
B.II.d.1.e - Change in the specification parameters 
25/07/2019 
n/a 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
IB/0026/G 
This was an application for a group of variations. 
11/07/2019 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0025 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/05/2019 
28/06/2019 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IA/0024/G 
This was an application for a group of variations. 
11/04/2019 
n/a 
Page 4/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0023 
B.II.b.2.c.1 - Change to importer, batch release 
21/03/2019 
28/06/2019 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0021 
B.III.2.z - Change to comply with Ph. Eur. or with a 
04/01/2019 
n/a 
national pharmacopoeia of a Member State - Other 
variation 
IB/0020 
C.I.2.a - Change in the SPC, Labelling or PL of a 
02/07/2018 
28/06/2019 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
T/0019 
Transfer of Marketing Authorisation 
18/04/2018 
08/05/2018 
SmPC, 
Page 5/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0018/G 
This was an application for a group of variations. 
18/01/2018 
08/05/2018 
SmPC and PL 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0017/G 
This was an application for a group of variations. 
27/10/2017 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
Page 6/12 
 
 
 
 
 
 
 
 
 
 
 
 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0016 
C.I.2.a - Change in the SPC, Labelling or PL of a 
01/08/2017 
08/05/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
R/0015 
Renewal of the marketing authorisation. 
15/12/2016 
23/02/2017 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Docetaxel Kabi in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. Risk 
Management Plan (Version 1.0) is introduced. 
IB/0014 
B.II.b.3.a - Change in the manufacturing process of 
12/07/2016 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0013 
B.III.1.a.1 - Submission of a new/updated or 
01/06/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IB/0012 
C.I.2.a - Change in the SPC, Labelling or PL of a 
15/12/2015 
12/12/2016 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 7/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0011 
C.I.8.a - Introduction of or changes to a summary of 
16/07/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IA/0010/G 
This was an application for a group of variations. 
16/07/2015 
n/a 
B.II.e.7.a - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
B.II.b.5.b - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Addition of a new test(s) and limits 
PSUSA/1152/
Periodic Safety Update EU Single assessment - 
25/09/2014 
n/a 
PRAC Recommendation - maintenance 
201311 
docetaxel 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
17/07/2014 
03/07/2015 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0007 
Update of section 4.4 and 4.5 of the SmPC in order 
19/03/2014 
22/05/2014 
SmPC 
to add a warning and update the safety information 
on interactions with CYP3A4 inhibitors further to the 
PRAC assessment of a signal. In addition, some 
inconsistencies have been rectified on the number 
and grade of alopecia adverse reactions in section 
Page 8/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.8 of the SmPC. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0006/G 
This was an application for a group of variations. 
17/10/2013 
22/05/2014 
SmPC and PL 
Update of the SmPC following the assessment of the 
same changes for the reference product, Taxotere. 
Sections 4.4 and 4.8 of the SmPC are updated in 
order to add a warning related to respiratory 
disorders and to include interstitial pneumonitis, 
interstitial lung disease and pulmonary fibrosis as 
new adverse reactions observed the post-marketing 
setting following a relevant cumulative review of the 
originator product’s safety database. The Package 
Leaflet is updated accordingly. In addition, Annex II 
is being brought in line with QRD template version 
8.3. 
Furthermore, minor linguistic and typographical 
errors were rectified for the German, Hungarian and 
Lithuanian annexes. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 9/12 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0005 
Update of the SmPC following the assessment of the 
29/05/2013 
22/05/2014 
SmPC, Annex 
same changes for the reference product, Taxotere. 
II and PL 
Sections 4.4 and 4.8 of the SmPC are updated in 
order to add a warning related to respiratory 
disorders and to include interstitial pneumonitis, 
interstitial lung disease and pulmonary fibrosis as 
new adverse reactions observed the post-marketing 
setting following a relevant cumulative review of the 
originator product’s safety database. The Package 
Leaflet is updated accordingly. In addition, Annex II 
is being brought in line with QRD template version 
8.3. 
Furthermore, minor linguistic and typographical 
errors were rectified for the German, Hungarian and 
Lithuanian annexes. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
Page 10/12 
 
 
 
 
 
 
 
 
 
II/0001/G 
This was an application for a group of variations. 
15/11/2012 
15/11/2012 
To change the manufacturing process of the active 
substance.  
The storage condition for Docetaxel anhydrous has 
been revised to comply with the Ph.Eur.  
To tight some specifications limits. 
To add new specification parameters to the 
specification with its corresponding test methods. 
To delete of non-significant specification parameters 
(UV and melting point). 
B.I.a.2.b - Changes in the manufacturing process of 
the AS - Substantial change to the manufacturing 
process of the AS which may have a significant 
impact on the quality, safety or efficacy of the 
medicinal product 
B.I.d.1.b.3 - Stability of AS - Change in the storage 
conditions - Change in storage conditions of the AS 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
Page 11/12 
 
 
 
 
 
 
 
 
 
an obsolete parameter) 
II/0002 
Addition of pack size of 20 mg/1 ml to Docetaxel 
20/09/2012 
29/10/2012 
SmPC, Annex 
Kabi 20 mg/ml Concentrate for Solution for Infusion. 
B.II.e.5.c - Change in pack size of the finished 
product - Change in the fill weight/fill volume of 
sterile multidose (or single-dose, partial use) 
parenteral medicinal products, and 
biological/immunological multidose parenteral 
medicinal products 
II, Labelling 
and PL 
Page 12/12 
 
 
 
 
 
 
 
 
 
 
